EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Epidemiology of Gaucher Disease in France: Trends in Incidence, Mortality, Management, and Complications Over Three Decades

Yann Nguyen iD, Maxime Beydon, Karima Yousfi, Samira Zebiche, Dalil Hamroun, Anaïs Brassier, Samia Pichard, Laure Swiader, Thierry Billette de Villemeur, Bénédicte Héron, Florence Dalbies, Bérengère Cador und 21 weitere

Journal of Inherited Metabolic Disease · 2025-05 · 48 (3)

DOI: 10.1002/jimd.70037 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Inherited Metabolic Disease, online erschienen am 09.05.2025. Verfasst von Yann Nguyen und 32 weiteren Autor:innen. Beteiligte Einrichtung: Service de Médecine Interne, Centre de référence des maladies lysosomales, Hôpital Beaujon, AP-HP.Nord, Université Paris Cité, Clichy, France. Hauptthemen laut MEDLINE: Gaucher Disease. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Takeda Pharmaceutical Company, Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gaucher disease (GD) is a rare autosomal‐recessive lysosomal disorder caused by glucocerebrosidase deficiency. In this study, we described the epidemiology of GD in France over more than three decades. The French GD registry (FGDR) includes all known patients with GD in France. We described patients' characteristics, and estimated the incidence, prevalence, and standardized mortality ratios of GD. We compared the evolution of diagnostic methods, diagnosis delays, and treatment over time, and assessed the incidence of bone events, malignancies, and Parkinson's disease. Between 1980 and 2024, 706 confirmed GD were included. In 2024, 447 patients were alive (413 type 1, 34 type 3). GD incidence was 0.21/1 000 000 PY, and GD prevalence was 0.61 and 0.05/100 000 inhabitants for type 1 and 3, respectively. The standardized mortality ratio was 0.70 for type 1 GD and 16.23 for type 3 GD. Over time, we observed a decrease in the delay between first symptoms and diagnosis (5.4 years before 2000; 0.8 after 2020; p = 0.001), with enzyme assays becoming the primary diagnostic method, a reduction in splenectomies, and a gradual increase in the use of substrate reduction therapy in type 1 GD. The incidences of bone events, malignancies, and Parkinson's disease were 23, 2.7, and 1.07 per 1000 person‐years, respectively. This study provides updated epidemiological data on GD in France, showing improvements in disease knowledge, faster and less invasive diagnoses, and reassuring outcomes for type 1 GD, with lower mortality and a relatively low incidence of malignancies and Parkinson's disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gaucher DiseaseHumansFranceIncidenceMaleFemaleMiddle AgedAdultRegistriesAdolescentAgedYoung AdultChildInfantChild, PreschoolPrevalence

Stichwörter der Autor:innen

Gaucher diseaseenzyme replacement therapyepidemiologylysosomal disorderregistrysubstrate reduction therapy

Autor:innen und Institutionen

  • Service de Médecine Interne, Centre de référence des maladies lysosomales, Hôpital Beaujon, AP-HP.Nord, Université Paris Cité, Clichy, France.
  • Centre de Recherche en Epidémiologie et Statistiques (CRESS), Unité Inserm 1153, Université Paris Cité, Paris, France.
  • Pôle Recherche & Innovation, CHU de Montpellier, Montpellier, France.
  • Centre de Référence des Maladies Lysosomales, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, IHU Institut Imagine, Paris, France.
  • Service de Médecine Interne, Hôpital La Timone, Assistance Publique-Hôpitaux de Marseille, Marseille, France.
  • Service de Neurologie Pédiatrique, Centre de Référence des Maladies Lysosomales, Hôpital Armand Trousseau-La Roche Guyon, Fédération Hospitalo-Universitaire I2-D2, APHP.Sorbonne Université, Paris, France.

ORCID-Profile: Yann Nguyen

Förderung

  • Takeda Pharmaceutical Company
  • Sanofi

Zitieren

APA

Nguyen, Y., Beydon, M., Yousfi, K., Zebiche, S., Hamroun, D., Brassier, A., Pichard, S., Swiader, L., Billette de Villemeur, T., Héron, B., Dalbies, F., Cador, B., Guemann, A. S., Gaches, F., Hivert, B., Leguy-Seguin, V., Masseau, A., Deshayes, R., Pers, Y. M., …, & French Evaluation of Gaucher Disease Treatment Committee (2025). Epidemiology of Gaucher Disease in France: Trends in Incidence, Mortality, Management, and Complications Over Three Decades. Journal of Inherited Metabolic Disease, 48(3). https://doi.org/10.1002/jimd.70037

Vancouver

Nguyen Y, Beydon M, Yousfi K, Zebiche S, Hamroun D, Brassier A, et al. Epidemiology of Gaucher Disease in France: Trends in Incidence, Mortality, Management, and Complications Over Three Decades. Journal of Inherited Metabolic Disease. 2025;48(3). doi:10.1002/jimd.70037

BibTeX
@article{Nguyen2025,
  author = {Nguyen, Yann and Beydon, Maxime and Yousfi, Karima and Zebiche, Samira and Hamroun, Dalil and Brassier, Anaïs and Pichard, Samia and Swiader, Laure and Billette de Villemeur, Thierry and Héron, Bénédicte and Dalbies, Florence and Cador, Bérengère and Guemann, Anne-Sophie and Gaches, Francis and Hivert, Bénédicte and Leguy-Seguin, Vanessa and Masseau, Agathe and Deshayes, Robin and Pers, Yves-Marie and Pettazzoni, Magali and Bekri, Soumeya and Caillaud, Catherine and Le Guillou, Edouard and Szymanowski, Marie and Astudillo, Leonardo and Mauhin, Wladimir and Nadjar, Yann and Serratrice, Christine and Berger, Marc G and Camou, Fabrice and Belmatoug, Nadia and Stirnemann, Jérôme and French Evaluation of Gaucher Disease Treatment Committee, French Evaluation of Gaucher Disease Treatment Committee},
  title = {Epidemiology of Gaucher Disease in France: Trends in Incidence, Mortality, Management, and Complications Over Three Decades},
  journal = {Journal of Inherited Metabolic Disease},
  year = {2025},
  volume = {48},
  number = {3},
  doi = {10.1002/jimd.70037}
}
Kostenlos starten →